David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...
Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.
The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...
Patients who received nivolumab had longer DFS than those who received standard care. OS will be evaluated after a prespecified number of deaths occur. The addition of adjuvant nivolumab to ...
Opdivo (nivolumab) is a prescription drug used ... If you’re treating esophageal cancer or stomach cancer with Opdivo, you may take Opdivo on its own or in combination with other medications.
Medical Xpress on MSN10d
Phase III trial shows new treatment boosts cure rate for most common form of breast cancerA Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...
healthday on MSN1d
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast CancerFor patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (H ...
Hosted on MSN1mon
Bristol Myers Squibb Stock In Focus After FDA Approves Cancer Drug: Retail Sentiment BrightensA total of 495 patients were randomized to receive either “subcutaneous nivolumab ... lung cancer; head and neck squamous cell carcinoma; colorectal cancer, hepatocellular carcinoma, esophageal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback